Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 167

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 167
---
 are deficiencies or irregularities in the business management practices of our company, including in consultation with our internal 
 auditor or the independent auditor, and making recommendations to the board of directors to improve such practices;                 |

| ● | determining the approval                                                                                               
 process for transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; |

| ● | determining whether to                                                                                                           
 approve certain related party transactions (including transactions in which an office holder has a personal interest and whether 
 such transaction is extraordinary or material under Companies Law) (see “— Approval of Related Party Transactions                
 under Israeli Law”);                                                                                                             |

| ● | where the board of directors                                                                                                        
 approves the working plan of the internal auditor, to examine such working plan before its submission to the board of directors and 
 proposing amendments thereto;                                                                                                       |

| ● | examining our internal                                                                                                            
 controls and internal auditor’s performance, including whether the internal auditor has sufficient resources and tools to dispose 
 of its responsibilities;                                                                                                          |

| ● | examining the scope of                                                                                                         
 our independent auditor’s work and compensation and submitting a recommendation with respect thereto to our board of directors 
 or shareholders, depending on which of them is considering the appointment of our independent auditor; and                     |

| ● | establishing procedures                                                                                                             
 for the handling of employees’ complaints as to the management of our business and the protection to be provided to such employees. |

Compensation Committee and Compensation Policy

We have established a compensation
committee to be effective as of the effective time of the registration statement to which this prospectus relates. The members of this
committee will be Mr. Keith Valentine, Mr. Pini Ben-Elazar, and Mr. Cohen-Arazi. Mr. Cohen-Arazi will serve as the chairperson of the
committee.

<div align='center'>102</div>

Israeli Companies Law Requirements

Under the Companies Law,
the board of directors of a public company must appoint a compensation committee. The duties of the compensation committee include the
recommendation to our board of directors of a policy regarding the terms of engagement of office holders (as defined in the Companies
Law), to which we refer as a compensation policy. The term “office holder” is defined under the Companies Law as a chief
executive officer (referred to in the Companies Law as the general manager), chief business manager, deputy general manager, vice general
manager, any other person assuming the responsibilities of any of these positions regardless of that person’s title, a director
and